Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

Tamada, S; Kondoh, C; Matsubara, N; Mizuno, R; Kimura, G; Anai, S; Tomita, Y; Oyama, M; Masumori, N; Kojima, T; Matsumoto, H; Chen, M; Li, MR; Matsuda, K; Tanaka, Y; Rini, BI; Uemura, H

Tamada, S (通讯作者)，Bell Land Gen Hosp, Naka Ku, Higashiyama 500-3, Sakai, Osaka 5998247, Japan.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022; 27 (1): 154

Abstract

Background In the phase III open-label KEYNOTE-426 (NCT02853331) study, first-line pembrolizumab and axitinib improved overall survival (OS) and progr......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索